Business · Companies · 4 hrs ago
Ozon Pharma registers its first domestically made biologic
Ozon Pharma's Mabscale unit registered Adalitril, the group's first biologic medicine.
It is made through the full production cycle at a facility in Tolyatti, Russia, and is a biosimilar of adalimumab.
The medicine treats chronic immune-related inflammatory diseases, including rheumatoid arthritis, Crohn's disease and ulcerative colitis, in adults and children.
Adalimumab blocks a protein involved in inflammation, helping control the immune response.
Russia's adalimumab market was worth 3.5 billion roubles in 2025, and five biosimilars were registered in the country by September 2026.
The medicine is on Russia's list of essential medicines, with prices regulated by the state, and access to biologic treatment remains below estimated patient need.
Commercial sales are planned in the coming months, but supply volumes and dates have not yet been set.
The company is also pursuing other biologic medicines, including trastuzumab, which is awaiting approval.
Ozon Pharma group has registered Adalitril, its first biotechnology medicine developed and produced through a full cycle in Russia.
The drug is an adalimumab biosimilar made at a production site in Tolyatti.
Adalimumab is used to treat chronic immune-inflammatory diseases, including rheumatoid arthritis and Crohn’s disease.
Commercial sales are planned to begin in the coming months, but supply volumes and dates have not been set.
The company says the launch demonstrates its ability to make biotechnology medicines domestically and could help expand access to treatment.
- Who
- Mabscale, part of the Ozon Pharma group, registered Adalitril.
- What
- Adalitril, the group’s first biotechnology medicine, received state registration as an adalimumab biosimilar.
- When
- 3 November 2026. Commercial sales are planned to begin in the coming months.
- Where
- The medicine was developed and produced through a full cycle at a site in Tolyatti, Russia.
- Why
- The company says domestic biosimilar production can support medicine security and make treatment more accessible.
This story does not have two clearly opposing sides.
The Russian adalimumab market was valued at 3.5 billion rubles, including VAT, according to company data cited by Vedomosti.
Five adalimumab biosimilars were registered in Russia, according to Vedomosti.
Mabscale announced that Adalitril had received state registration.
The company plans to begin commercial sales, though final supply volumes and dates have not been determined.
- Drug
- Adalitril, an adalimumab biosimilar
- Developer and producer
- Mabscale, part of Ozon Pharma
- Production site
- Tolyatti, Russia
- Dose and form
- 40 mg/0.8 ml solution in prefilled single-use syringes
- Russian adalimumab market
- 3.5 billion rubles in 2025, including VAT
- Registered biosimilars
- Five in Russia as of September 2026
3 sources
What people are saying
запуск «Адалитрила» подтверждает возможность создания в России биотехнологического производства полного цикла – от клеточной линии до готовой лекарственной формы
выпуск отечественных биопрепаратов позволяет обеспечить лечением больше пациентов в рамках того же бюджета системы здравоохранения